171 related articles for article (PubMed ID: 37728734)
1. Real-world effectiveness and safety of stereotactic body radiotherapy for liver metastases with different respiratory motion management techniques.
Hernando-Requejo O; Chen X; López M; Sánchez E; García J; García P; Alonso R; Montero A; Ciervide R; Álvarez B; Zucca D; García Aranda M; Valero J; Fernández Letón P; Rubio C
Strahlenther Onkol; 2023 Nov; 199(11):1000-1010. PubMed ID: 37728734
[TBL] [Abstract][Full Text] [Related]
2. The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases.
Andratschke N; Alheid H; Allgäuer M; Becker G; Blanck O; Boda-Heggemann J; Brunner T; Duma M; Gerum S; Guckenberger M; Hildebrandt G; Klement RJ; Lewitzki V; Ostheimer C; Papachristofilou A; Petersen C; Schneider T; Semrau R; Wachter S; Habermehl D
BMC Cancer; 2018 Mar; 18(1):283. PubMed ID: 29534687
[TBL] [Abstract][Full Text] [Related]
3. SBRT-SG-01: final results of a prospective multicenter study on stereotactic body radiotherapy for liver metastases.
Rodríguez MR; Chen-Zhao X; Hernando O; Flamarique S; Fernández-Letón P; Campo M; López M; Rodríguez M; Zucca D; Martínez D; Sánchez-Saugar E; Mañeru F; Ruiz-Zorrilla JG; de Acilu PG; Valero J; Montero A; Ciérvide R; Alvarez B; García-Aranda M; Alonso R; de la Casa MA; Alonso L; Nuñez M; Martí J; Arias F
Clin Transl Oncol; 2024 Jul; 26(7):1790-1797. PubMed ID: 38431539
[TBL] [Abstract][Full Text] [Related]
4. Role of stereotactic body radiation therapy in the treatment of liver metastases: clinical results and prognostic factors.
Clerici E; Comito T; Franzese C; Di Brina L; Tozzi A; Iftode C; Navarria P; Mancosu P; Reggiori G; Tomatis S; Scorsetti M
Strahlenther Onkol; 2020 Apr; 196(4):325-333. PubMed ID: 31605163
[TBL] [Abstract][Full Text] [Related]
5. A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases.
Fumagalli I; Bibault JE; Dewas S; Kramar A; Mirabel X; Prevost B; Lacornerie T; Jerraya H; Lartigau E
Radiat Oncol; 2012 Sep; 7():164. PubMed ID: 23014094
[TBL] [Abstract][Full Text] [Related]
6. Additional chemotherapy improved local control and overall survival after stereotactic body radiation therapy for patients with oligo-recurrence.
Nakamura M; Hashimoto N; Mayahara H; Uezono H; Harada A; Nishikawa R; Matsuo Y; Kawaguchi H; Nishimura H
Radiat Oncol; 2018 Apr; 13(1):75. PubMed ID: 29688858
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of Stereotactic Body Radiation Therapy for patient with unresectable liver metastases from colorectal cancer.
Py JF; Salleron J; Courrech F; Beckendorf V; Croisé-Laurent V; Peiffert D; Vogin G; Dietmann AS
Cancer Radiother; 2021 Jun; 25(4):350-357. PubMed ID: 33618909
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".
Rieber J; Streblow J; Uhlmann L; Flentje M; Duma M; Ernst I; Blanck O; Wittig A; Boda-Heggemann J; Krempien R; Lohaus F; Klass ND; Eble MJ; Imhoff D; Kahl H; Petersen C; Gerum S; Henkenberens C; Adebahr S; Hass P; Schrade E; Wendt TG; Hildebrandt G; Andratschke N; Sterzing F; Guckenberger M
Lung Cancer; 2016 Jul; 97():51-8. PubMed ID: 27237028
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up.
Scorsetti M; Comito T; Clerici E; Franzese C; Tozzi A; Iftode C; Di Brina L; Navarria P; Mancosu P; Reggiori G; Fogliata A; Tomatis S; Torzilli G; Cozzi L
Radiat Oncol; 2018 Nov; 13(1):234. PubMed ID: 30477560
[TBL] [Abstract][Full Text] [Related]
10. Liver SBRT with active motion-compensation results in excellent local control for liver oligometastases: An outcome analysis of a pooled multi-platform patient cohort.
Stera S; Miebach G; Buergy D; Dreher C; Lohr F; Wurster S; Rödel C; Marcella S; Krug D; Frank A G; Ehmann M; Fleckenstein J; Blanck O; Boda-Heggemann J
Radiother Oncol; 2021 May; 158():230-236. PubMed ID: 33667585
[TBL] [Abstract][Full Text] [Related]
11. Local Control Outcomes Using Stereotactic Body Radiation Therapy for Liver Metastases From Colorectal Cancer.
Joo JH; Park JH; Kim JC; Yu CS; Lim SB; Park IJ; Kim TW; Hong YS; Kim KP; Yoon SM; Park J; Kim JH
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):876-883. PubMed ID: 29063852
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic Body Radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch® Patient Registry.
Mahadevan A; Blanck O; Lanciano R; Peddada A; Sundararaman S; D'Ambrosio D; Sharma S; Perry D; Kolker J; Davis J
Radiat Oncol; 2018 Feb; 13(1):26. PubMed ID: 29439707
[TBL] [Abstract][Full Text] [Related]
13. The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases.
Klement RJ; Abbasi-Senger N; Adebahr S; Alheid H; Allgaeuer M; Becker G; Blanck O; Boda-Heggemann J; Brunner T; Duma M; Eble MJ; Ernst I; Gerum S; Habermehl D; Hass P; Henkenberens C; Hildebrandt G; Imhoff D; Kahl H; Klass ND; Krempien R; Lewitzki V; Lohaus F; Ostheimer C; Papachristofilou A; Petersen C; Rieber J; Schneider T; Schrade E; Semrau R; Wachter S; Wittig A; Guckenberger M; Andratschke N
BMC Cancer; 2019 Feb; 19(1):173. PubMed ID: 30808323
[TBL] [Abstract][Full Text] [Related]
14. Clinical results of mean GTV dose optimized robotic guided SBRT for liver metastases.
Andratschke N; Parys A; Stadtfeld S; Wurster S; Huttenlocher S; Imhoff D; Yildirim M; Rades D; Rödel CM; Dunst J; Hildebrandt G; Blanck O
Radiat Oncol; 2016 May; 11():74. PubMed ID: 27236333
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic Body Radiotherapy (SBRT) for Spinal Metastases: Who Will Benefit the Most from SBRT?
Park HJ; Kim HJ; Won JH; Lee SC; Chang AR
Technol Cancer Res Treat; 2015 Apr; 14(2):159-67. PubMed ID: 24502552
[TBL] [Abstract][Full Text] [Related]
16. Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy.
Franzese C; Comito T; Franceschini D; Loi M; Clerici E; Navarria P; De Rose F; Di Brina L; Mancosu P; Reggiori G; Tomatis S; Scorsetti M
J Cancer Res Clin Oncol; 2020 May; 146(5):1227-1234. PubMed ID: 32056005
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic radiation therapy for liver metastases: factors affecting local control and survival.
Andratschke NH; Nieder C; Heppt F; Molls M; Zimmermann F
Radiat Oncol; 2015 Mar; 10():69. PubMed ID: 25889512
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, toxicities, and prognostic factors of stereotactic body radiotherapy for unresectable liver metastases.
Choi CKK; Ho CHM; Wong MYP; Leung RWK; Wong FCS; Tung SY; Lee FAS
Hong Kong Med J; 2023 Apr; 29(2):105-111. PubMed ID: 36990676
[TBL] [Abstract][Full Text] [Related]
19. Single-institutional outcome-analysis of low-dose stereotactic body radiation therapy (SBRT) of adrenal gland metastases.
Voglhuber T; Kessel KA; Oechsner M; Vogel MME; Gschwend JE; Combs SE
BMC Cancer; 2020 Jun; 20(1):536. PubMed ID: 32513136
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients.
König L; Häfner MF; Katayama S; Koerber SA; Tonndorf-Martini E; Bernhardt D; von Nettelbladt B; Weykamp F; Hoegen P; Klüter S; Susko MS; Debus J; Hörner-Rieber J
Radiat Oncol; 2020 Feb; 15(1):30. PubMed ID: 32019553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
